- Home
- DEVS vs NXTC Comparison
DEVS vs NXTC Comparison
Compare DEVS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- NXTC
- Stock Information
- Founded
- DEVS N/A
- NXTC 2015
- Country
- DEVS Canada
- NXTC United States
- Employees
- DEVS N/A
- NXTC N/A
- Industry
- DEVS
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- NXTC Health Care
- Exchange
- DEVS NYSE
- NXTC Nasdaq
- Market Cap
- DEVS 11.9M
- NXTC 13.9M
- IPO Year
- DEVS N/A
- NXTC 2019
- Fundamental
- Price
- DEVS $0.34
- NXTC $0.40
- Analyst Decision
- DEVS
- NXTC Strong Buy
- Analyst Count
- DEVS 0
- NXTC 2
- Target Price
- DEVS N/A
- NXTC $3.50
- AVG Volume (30 Days)
- DEVS 524.3K
- NXTC 341.5K
- Earning Date
- DEVS 07-22-2025
- NXTC 07-31-2025
- Dividend Yield
- DEVS N/A
- NXTC N/A
- EPS Growth
- DEVS N/A
- NXTC N/A
- EPS
- DEVS N/A
- NXTC N/A
- Revenue
- DEVS $10,164.00
- NXTC N/A
- Revenue This Year
- DEVS N/A
- NXTC N/A
- Revenue Next Year
- DEVS N/A
- NXTC N/A
- P/E Ratio
- DEVS N/A
- NXTC N/A
- Revenue Growth
- DEVS N/A
- NXTC N/A
- 52 Week Low
- DEVS $0.18
- NXTC $0.22
- 52 Week High
- DEVS $3.00
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- NXTC 37.68
- Support Level
- DEVS N/A
- NXTC $0.42
- Resistance Level
- DEVS N/A
- NXTC $0.50
- Average True Range (ATR)
- DEVS 0.00
- NXTC 0.04
- MACD
- DEVS 0.00
- NXTC -0.01
- Stochastic Oscillator
- DEVS 0.00
- NXTC 4.17
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.